Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostatic Neoplasms × Cefazolin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Infections 2 Wound Infection 1 Surgical Wound Infection 1 Prostatic Neoplasms 1 Laryngeal Neoplasms 1 Bone Neoplasms 1

Interventions

Prednisone 48 Radiotherapy 45 Docetaxel 45 Leuprolide 41 Goserelin 41 bicalutamide 40 enzalutamide 26 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 26 Androgen Antagonists 23 Flutamide 21 Triptorelin Pamoate 20 apalutamide 18 Gonadotropin-Releasing Hormone 15 Abiraterone Acetate 15 Zoledronic Acid 13 Radiation 12 Magnetic Resonance Spectroscopy 12 gallium 68 PSMA-11 11 abiraterone 11 Prednisolone 9 cabazitaxel 8 Estramustine 8 Dexamethasone 8 Buserelin 8 luprolide acetate gel depot 7 darolutamide 7 Standard of Care 7 Specimen Handling 7 Radiotherapy, Conformal 7 Mitoxantrone 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03862170 2025-02-12

BRP30

CR-CSSS Champlain-Charles-Le Moyne

Phase 3 Terminated

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡